Last $7.54 USD
Change Today 0.00 / 0.00%
Volume 0.0
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 08:30 AM

ImmunoGen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 08:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.

ImmunoGen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014; Reaffirms Earnings Guidance for the Full Year of Fiscal 2015

ImmunoGen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, total revenues were $48,300,000 against $30,060,000 a year ago. Income from operations was $13,781,000 against $3,751,000 a year ago. Net income was $13,635,000 against $3,813,000 a year ago. Basic and diluted net income per common share was $0.16 against $0.04 a year ago. Capital expenditures were $2.6 million in the second quarter, which was consistent with $2.3 million in the same quarter last year. The company reported second quarter adjusted EPS of $0.16, up from $0.04. For the six months, total revenues were $61,503,000 against $47,278,000 a year ago. Income from operations was $8,129,000 against $7,586,000 a year ago. Net loss was $8,647,000 against net income of $7,414,000 a year ago. Basic and diluted net loss per common share was $0.10 against $0.09 a year ago. Cash used in operations was $34.4 million compared to $21.6 million in the same period last year, reflecting increased investment in advancing wholly owned programs. The company reaffirmed earnings guidance for the full year of fiscal 2015, its revenues to be between $100 million and $105 million; its net loss to be between $60 million and $65 million; its cash used in operations to be between $55 million and $60 million; and its capital expenditures to be between $7 million and $9 million.

ImmunoGen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:30 AM

ImmunoGen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:30 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.

ImmunoGen, Inc. to Report Q2, 2015 Results on Jan 30, 2015

ImmunoGen, Inc. announced that they will report Q2, 2015 results at 8:00 AM, US Eastern Standard Time on Jan 30, 2015

ImmunoGen, Inc., Q2 2015 Earnings Call, Jan 30, 2015

ImmunoGen, Inc., Q2 2015 Earnings Call, Jan 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $7.54 USD 0.00

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.60 EUR +0.05
Abzena PLC 82.00 GBp 0.00
BioInvent International AB kr2.36 SEK -0.03
Genmab A/S kr514.50 DKK -4.00
MorphoSys AG €72.42 EUR -1.04
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.